Sort
10,766 grants matching “checkpoint inhibitor”
INDUCTION OF P21 AND P27 IN LIVER AFTER CCL4 INJURY
$258,025University Of Illinois At Chicago · R01 · FY2003 · DK
Antibody blockade of T cell activating co-inhibitory receptor KLRG1 for treatment of melanoma
$257,932Stefano Gulla · Abcuro, Inc. · R43 · FY2019 · CA
Modulating the DNA Damage Repair System in Traumatic Optic Neuropathy
$257,785Benyam Z Kinde · Stanford University · K08 · FY2025 · EY
Molecular Pharmacology & Biochemistry of Dual Specificity Phosphatase Inhibitors
$257,635John S Lazo · University Of Pittsburgh At Pittsburgh · P01 · FY2007 · CA
P53 MEDIATED G2/M CHECKPOINT CONTROL
$257,526Thomas Jefferson University · R01 · FY2003 · CA
CELL CYCLE REGULATION DURING SPERMATOGENESIS
$257,400University Of Tennessee Knoxville · R01 · FY2000 · HD
Intratumoral Administration of CCL21-gene Modified Dendritic Cell With Intravenous Pembrolizumab for Advanced NSCLC
$257,099Aaron Elliott Lisberg · University Of California Los Angeles · K08 · FY2024 · CA
Intratumoral Administration of CCL21-gene Modified Dendritic Cell With Intravenous Pembrolizumab for Advanced NSCLC
$257,099Aaron Elliott Lisberg · University Of California Los Angeles · K08 · FY2021 · CA
Intratumoral Administration of CCL21-gene Modified Dendritic Cell With Intravenous Pembrolizumab for Advanced NSCLC
$257,099Aaron Elliott Lisberg · University Of California Los Angeles · K08 · FY2023 · CA
Intratumoral Administration of CCL21-gene Modified Dendritic Cell With Intravenous Pembrolizumab for Advanced NSCLC
$257,099Aaron Elliott Lisberg · University Of California Los Angeles · K08 · FY2020 · CA
Intratumoral Administration of CCL21-gene Modified Dendritic Cell With Intravenous Pembrolizumab for Advanced NSCLC
$257,099Aaron Elliott Lisberg · University Of California Los Angeles · K08 · FY2022 · CA
Preclinical development and clinical monitoring of adoptive immune therapy
$257,070Francis Flomerfelt · Division Of Basic Sciences - Nci · ZIC · FY2021 · CA
Biological Functions of the Oncogenes Encoding Rho-Specific Exchange Factors
$256,839Toru Miki · Division Of Basic Sciences - Nci · Z01 · FY2008 · CA
Transcriptional silencing by the BCL6 oncoprotein
$256,823Ari M. Melnick · Weill Medical Coll Of Cornell Univ · R01 · FY2012 · CA
PDGF Regulation of Cell Growth and Death
$256,820Wayne State University · R01 · FY2002 · CA
Core 1: Mouse Model and Tissue Biobank Core
$256,772Roger S Lo · Institute For Systems Biology · U54 · FY2024 · CA
Early Clinical Trials of New Anti-Cancer Agents with Phase 1 Emphasis
$256,656David R Spriggs · Sloan-Kettering Inst Can Research · U01 · FY2009 · CA
Development of Sapacitabine Therapy in Leukemias
$256,449William K Plunkett · University Of Tx Md Anderson Can Ctr · P50 · FY2009 · CA
MODULATION OF HOST CELL APOPTOTIC RESPONSES BY HPVE7
$256,270Harvard University (Medical School) · R01 · FY2002 · CA
CHARACTERIZING AGGRESSIVE GLIOMA COPY NUMBER SUBTYPES
$256,230Patrick J. Cimino · University Of Washington · K08 · FY2020 · CA
CHARACTERIZING AGGRESSIVE GLIOMA COPY NUMBER SUBTYPES
$256,230Patrick J. Cimino · University Of Washington · K08 · FY2021 · CA
DC AML Fusion Cell Vaccination with Immune checkpoint Blockade
$256,093Gordon James Freeman · Brigham And Women'S Hospital · P50 · FY2017 · CA
"Optimizing synthetic lethality in high-grade serous ovarian cancer"
$256,092Fiona Simpkins · Johns Hopkins University · P50 · FY2021 · CA
Metabolic adaptation enables cisplatin resistance and inhibits tumor immunity
$255,987Vlad C Sandulache · University Of Tx Md Anderson Can Ctr · U54 · FY2023 · CA
Targeting the Progesterone Receptor as a Novel Means to Increase Efficacy of Immune Checkpoint Inhibitors in Hormone Receptor Positive Breast Cancer
$255,588Christy Hagan · University Of Kansas Medical Center · R21 · FY2022 · CA